Jefferies Lowers PT on Alibaba Stock to $153, Maintains Buy Rating
Thomas Chong from Jefferies slightly reduced the price target on BABA, citing increased investment in food delivery and logistics. Chong remains positive about Alibaba and said that its on-demand services, including Eleme and Taobao Instant Commerce, managed over 60 million daily orders in late June. This remarkable development could help Alibaba drive user growth and engagement, Chong mentioned.
Christopher Penler / Shutterstock.com
Alibaba has lately been investing in AI, and analysts see a major upside for the company, backed by its AI investments. Recently, Alibaba Group Holding Limited (NYSE:BABA) launched a new AI model for image generation called Qwen VLo. The model builds on the earlier Qwen 2.5 vision language system and offers advanced features for generating and editing images. The latest image generation AI model supports both text-to-image and image-to-image generation.
Alibaba Group Holding Limited (NYSE:BABA) is a leading Chinese e-commerce platform. It is a diversified company with a major share in cloud services and a growing presence in Gen AI.
While we acknowledge the potential of BABA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
18 minutes ago
- Business Insider
Jefferies Sticks to Its Buy Rating for Nayax (NYAX)
In a report released on July 2, Hannes Leitner from Jefferies maintained a Buy rating on Nayax, with a price target of ILs199.00. The company's shares closed last Thursday at ILA17,000.00. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Leitner covers the Technology sector, focusing on stocks such as Worldline, Adyen, and Wise PLC Class A. According to TipRanks, Leitner has an average return of 17.3% and a 66.67% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nayax with a ILA15,071.14 average price target.
Bloomberg
33 minutes ago
- Bloomberg
Nvidia Partner Hon Hai Meets Sales Estimates on Strong AI Demand
Hon Hai Precision Industry Co. reported 15.8% growth in quarterly sales on robust demand for AI servers and iPhones. Revenue totaled NT$1.8 trillion ($62 billion) in the three months to June, largely in line with analysts' expectations, results showed Saturday. Hon Hai expects third-quarter sales to grow sequentially and year-on-year.
Yahoo
33 minutes ago
- Yahoo
Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment
Edgewise Therapeutics Inc. (NASDAQ:EWTX) is one of the best up and coming stocks to invest in now. On June 26, Edgewise Therapeutics announced positive results from its sevasemten program for Becker and Duchenne muscular dystrophies. For Becker muscular dystrophy, the company reported positive data from MESA, which is an open-label extension trial that provides continued access to sevasemten for participants previously enrolled in ARCH, CANYON, GRAND CANYON, or DUNE trials. Sevasemten maintained a favorable safety profile over up to 3 years of treatment. For Duchenne muscular dystrophy, Edgewise announced encouraging topline data from its Phase 2 LYNX and FOX trials. A scientist in a lab coat using a microscope to study a cultured biopharmaceutical product. Sevasemten is an orally administered and first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies like Becker and Duchenne. Becker muscular dystrophy is a rare, genetic, debilitating, and degenerative neuromuscular disorder primarily affecting males, with no currently approved therapies. Duchenne muscular dystrophy is a severe degenerative muscle disorder, the most common type of muscular dystrophy, with a median life expectancy of around 30 years. Edgewise Therapeutics Inc. (NASDAQ:EWTX) is a biopharmaceutical company that discovers, develops, and commercializes therapies for the treatment of muscle disorders. While we acknowledge the potential of EWTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
